BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27282309)

  • 1. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
    Hylebos M; Van Camp G; van Meerbeeck JP; Op de Beeck K
    J Thorac Oncol; 2016 Oct; 11(10):1615-26. PubMed ID: 27282309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
    Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
    Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
    Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Deletion of
    Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 12. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
    Louw A; Badiei A; Creaney J; Chai MS; Lee YCG
    Curr Opin Pulm Med; 2019 Jul; 25(4):354-361. PubMed ID: 31169558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
    Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
    Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
    Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
    J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.